{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:02:56Z","timestamp":1788469376994,"version":"build-2803163510"},"reference-count":221,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>It is commonly believed that the inactivation of inflammation is mainly due to the decay or cessation of inducers. In reality, in connection with the development of atherosclerosis, spontaneous decay of inducers is not observed. It is now known that lipid mediators originating from polyunsaturated fatty acids (PUFAs), which are important constituents of all cell membranes, can act in the inflamed tissue and bring it to resolution. In fact, PUFAs, such as arachidonic acid (AA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), are precursors to both pro-inflammatory and anti-inflammatory compounds. In this review, we describe the lipid mediators of vascular inflammation and resolution, and their biochemical activity. In addition, we highlight data from the literature that often show a worsening of atherosclerotic disease in subjects deficient in lipid mediators of inflammation resolution, and we also report on the anti-proteasic and anti-thrombotic properties of these same lipid mediators. It should be noted that despite promising data observed in both animal and in vitro studies, contradictory clinical results have been observed for omega-3 PUFAs. Many further studies will be required in order to clarify the observed conflicts, although lifestyle habits such as smoking or other biochemical factors may often influence the normal synthesis of lipid mediators of inflammation resolution.<\/jats:p>","DOI":"10.3390\/ijms24021637","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T02:04:45Z","timestamp":1673834685000},"page":"1637","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Classes of Lipid Mediators and Their Effects on Vascular Inflammation in Atherosclerosis"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1333-0423","authenticated-orcid":false,"given":"Valter","family":"Lubrano","sequence":"first","affiliation":[{"name":"Fondazione CNR-Regione Toscana G Monasterio, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1198-9822","authenticated-orcid":false,"given":"Rudina","family":"Ndreu","sequence":"additional","affiliation":[{"name":"Institute of Clinical Physiology, National Research Council, Via G. Moruzzi 1, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Balzan","sequence":"additional","affiliation":[{"name":"Institute of Clinical Physiology, National Research Council, Via G. Moruzzi 1, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/35025203","article-title":"Atherosclerosis","volume":"407","author":"Lusis","year":"2000","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-021-00198-1","article-title":"Targeting inflammation in atherosclerosis\u2014From experimental insights to the clinic","volume":"20","author":"Soehnlein","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1172\/JCI97950","article-title":"The role of non-resolving inflammation in atherosclerosis","volume":"128","author":"Kasikara","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2174\/092986732609190521112756","article-title":"The Role of Modified and Dysfunctional Lipoproteins in Atherogenesis","volume":"26","author":"Orekhov","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cell.2011.04.005","article-title":"Macrophages in the pathogenesis of atherosclerosis","volume":"145","author":"Moore","year":"2011","journal-title":"Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1096\/fj.08-112201","article-title":"Atherosclerosis: Evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators","volume":"22","author":"Merched","year":"2008","journal-title":"FASEB J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10741-019-09817-x","article-title":"Re-evaluating the causes and consequences of non-resolving inflammation in chronic cardiovascular disease","volume":"25","author":"Pullen","year":"2020","journal-title":"Heart Fail. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/joim.12406","article-title":"Inflammation and plaque vulnerability","volume":"278","author":"Hansson","year":"2015","journal-title":"J. Intern. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1161\/CIRCRESAHA.114.302721","article-title":"Mechanisms of plaque formation and rupture","volume":"114","author":"Bentzon","year":"2014","journal-title":"Circ. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"631398","DOI":"10.3389\/fcvm.2020.631398","article-title":"Anti-inflammatory Therapy for Coronary Atherosclerotic Heart Disease: Unanswered questions behind existing successes","volume":"7","author":"Ma","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.4049\/jimmunol.174.7.4345","article-title":"Molecular circuits of resolution: Formation and actions of resolvins and protectins","volume":"174","author":"Bannenberg","year":"2005","journal-title":"J. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/89759","article-title":"Lipid mediator class switching during acute inflammation: Signals in resolution","volume":"2","author":"Levy","year":"2001","journal-title":"Nat. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1100\/tsw.2002.81","article-title":"Lipid-Derived Mediators in Endogenous Anti-Inflammation and Resolution: Lipoxins and Aspirin-Triggered 15-epi-Lipoxins","volume":"2","author":"Serhan","year":"2002","journal-title":"Sci. World J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1146\/annurev.immunol.25.022106.141647","article-title":"Resolution Phase of Inflammation: Novel Endogenous Anti-Inflammatory and Proresolving Lipid Mediators and Pathways","volume":"25","author":"Serhan","year":"2007","journal-title":"Annu. Rev. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.2353\/ajpath.2010.100322","article-title":"Novel Lipid Mediators and Resolution Mechanisms in Acute Inflammation: To Resolve or Not?","volume":"177","author":"Serhan","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1128\/microbiolspec.MCHD-0035-2016","article-title":"Lipid Mediators in Inflammation","volume":"4","author":"Bennett","year":"2016","journal-title":"Microbiol. Spectr."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"12859","DOI":"10.1038\/ncomms12859","article-title":"An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques","volume":"7","author":"Fredman","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1161\/CIRCRESAHA.116.309492","article-title":"Resolving Lipid Mediators Maresin 1 and Resolvin D2 Prevent Atheroprogression in Mice","volume":"119","author":"Viola","year":"2016","journal-title":"Circ. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"838782","DOI":"10.3389\/fphar.2022.838782","article-title":"Formation, Signaling and Occurrence of Specialized Pro-Resolving Lipid Mediators\u2014What is the Evidence so far?","volume":"13","author":"Schebb","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/ni0208-113","article-title":"The cysteinyl leukotrienes: Where do they come from? What are they? Where are they going?","volume":"9","author":"Austen","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1172\/JCI200113455","article-title":"Genetic and pharmacological analysis of prostanoid receptor function","volume":"108","author":"Narumiya","year":"2001","journal-title":"J. Clin. Investig."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41392-020-00443-w","article-title":"Metabolism pathways of arachidonic acids: Mechanisms and potential therapeutic targets","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"997403","DOI":"10.3389\/fphar.2022.997403","article-title":"Eicosanoids in inflammation in the blood and the vessel","volume":"13","author":"Yamaguchi","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Idborg, H., and Pawelzik, S.-C. (2022). Prostanoid Metabolites as Biomarkers in Human Disease. Metabolites, 12.","DOI":"10.3390\/metabo12080721"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.biochem.69.1.145","article-title":"Cyclooxygenases: Structural, Cellular, and Molecular Biology","volume":"69","author":"Smith","year":"2000","journal-title":"Annu. Rev. Biochem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/ATVBAHA.119.313234","article-title":"Cardiovascular Biology of Prostanoids and Drug Discovery","volume":"40","author":"Zhu","year":"2020","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1124\/pr.110.003517","article-title":"International Union of Basic and Clinical Pharmacology. LXXXIII: Classification of Prostanoid Receptors, Updating 15 Years of Progress","volume":"63","author":"Woodward","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"32037","DOI":"10.1074\/jbc.M003873200","article-title":"Internalization and sequestration of the human prostacyclin receptor","volume":"275","author":"Smith","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.semarthrit.2006.03.005","article-title":"Prostaglandins in health and disease: An overview","volume":"Volume 36","author":"Miller","year":"2006","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"11613","DOI":"10.1074\/jbc.R600038200","article-title":"Prostaglandin E Receptors","volume":"282","author":"Sugimoto","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_31","first-page":"4702","article-title":"Prostaglandin E2 receptor EP4 is involved in the cell growth and invasion of prostate cancer via the cAMP-PKA\/PI3K-Akt signaling pathway","volume":"17","author":"Xu","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"ref_32","unstructured":"Rucker, D., and Dhamoon, A.S. (2022). Physiology, Thromboxane A2. StatPearls [Internet], StatPearls Publishing."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.prostaglandins.2017.11.004","article-title":"Role of thromboxane A2 signaling in endothelium-dependent contractions of arteries","volume":"134","author":"Chen","year":"2018","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0090-6980(02)00036-9","article-title":"Lipoxygenase genes and their targeted disruption","volume":"68\u201369","author":"Funk","year":"2002","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1126\/science.294.5548.1871","article-title":"Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology","volume":"294","author":"Funk","year":"2001","journal-title":"Science"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2432958","DOI":"10.1155\/2017\/2432958","article-title":"Role of the Cysteinyl Leukotrienes in the Pathogenesis and Progression of Cardiovascular Diseases","volume":"2017","author":"Colazzo","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"16695","DOI":"10.1073\/pnas.0808993105","article-title":"Functional recognition of a distinct receptor preferential for leukotriene E 4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors","volume":"105","author":"Maekawa","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.plipres.2018.11.001","article-title":"Emerging role of 12\/15-Lipoxygenase (ALOX15) in human pathologies","volume":"73","author":"Singh","year":"2019","journal-title":"Prog. Lipid Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0889-857X(03)00117-0","article-title":"Novel endogenous small molecules as the checkpoint controllers in inflammation and resolution: Entr\u00e9e for resoleomics","volume":"30","author":"Serhan","year":"2004","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"158940","DOI":"10.1016\/j.bbalip.2021.158940","article-title":"Lipoxins and synthetic lipoxin mimetics: Therapeutic potential in renal diseases","volume":"1866","author":"Andrews","year":"2021","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/ki.1995.184","article-title":"Transcellular biosynthesis of lipoxin A4 during adhesion of platelets and neutrophils in experimental immune complex glomerulonephritis","volume":"47","author":"Papayianni","year":"1995","journal-title":"Kidney Int."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/sj.bjp.0705912","article-title":"Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration","volume":"143","author":"Bannenberg","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1096\/fasebj.12.6.487","article-title":"Lipoxin B4regulates human monocyte\/neutrophil adherence and motility: Design of stable lipoxin B4analogs with increased biologic activity","volume":"12","author":"Maddox","year":"1998","journal-title":"FASEB J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1161\/CIRCULATIONAHA.115.020633","article-title":"Formyl-Peptide Receptor 2\/3\/Lipoxin A 4 Receptor Regulates Neutrophil-Platelet Aggregation and Attenuates Cerebral Inflammation: Impact for Therapy in Cardiovascular Disease","volume":"133","author":"Vital","year":"2016","journal-title":"Circulation"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"P163","DOI":"10.1016\/S0022-2275(20)32049-6","article-title":"Cytochrome P450 and arachidonic acid bioactivation: Molecular and functional properties of the arachidonate monooxygenase","volume":"41","author":"Capdevila","year":"2000","journal-title":"J. Lipid Res."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Shi, Z., He, Z., and Wang, D.W. (2022). CYP450 Epoxygenase Metabolites, Epoxyeicosatrienoic Acids, as Novel Anti-Inflammatory Mediators. Molecules, 27.","DOI":"10.3390\/molecules27123873"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"695","DOI":"10.33549\/physiolres.934291","article-title":"Epoxyeicosanoids in Hypertension","volume":"68","author":"Imig","year":"2019","journal-title":"Physiol. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1172\/JCI200421446","article-title":"Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice","volume":"114","author":"Kobayashi","year":"2004","journal-title":"J Clin Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"14507","DOI":"10.1073\/pnas.0606586103","article-title":"Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis","volume":"103","author":"Wang","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1161\/CIRCULATIONAHA.107.731398","article-title":"Microsomal Prostaglandin E Synthase-1 Deletion Suppresses Oxidative Stress and Angiotensin II\u2013Induced Abdominal Aortic Aneurysm Formation","volume":"117","author":"Wang","year":"2008","journal-title":"Circulation"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/ATVBAHA.118.310713","article-title":"Protective Role of mPGES-1 (Microsomal Prostaglandin E Synthase-1)\u2013Derived PGE2 (Prostaglandin E2) and the Endothelial EP4 (Prostaglandin E Receptor) in Vascular Responses to Injury","volume":"38","author":"Hao","year":"2018","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"H2428","DOI":"10.1152\/ajpheart.01120.2011","article-title":"Mice lacking macrophage 12\/15-lipoxygenase are resistant to experimental hypertension","volume":"302","author":"Kriska","year":"2012","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1440-1681.2011.05492.x","article-title":"Activation of peroxisome proliferator-activated receptor-\u03b3 downregulates soluble epoxide hydrolase in cardiomyocytes","volume":"38","author":"Pang","year":"2011","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_54","first-page":"71","article-title":"Role of platelet-activating factor in the reperfusion injury of rabbit ischemic heart","volume":"137","author":"Montrucchio","year":"1990","journal-title":"Am. J. Pathol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.2353\/ajpath.2010.090009","article-title":"Atherosclerotic Lesion Progression Changes Lysophosphatidic Acid Homeostasis to Favor its Accumulation","volume":"176","author":"Bot","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"eaal2722","DOI":"10.1126\/scisignal.aal2722","article-title":"An engineered S1P chaperone attenuates hypertension and ischemic injury","volume":"10","author":"Swendeman","year":"2017","journal-title":"Sci. Signal."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5396","DOI":"10.3390\/md12115396","article-title":"Resolvin D1, a Metabolite of Omega-3 Polyunsaturated Fatty Acid, Decreases Post-Myocardial Infarct Depression","volume":"12","author":"Gilbert","year":"2014","journal-title":"Mar. Drugs"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"H153","DOI":"10.1152\/ajpheart.01057.2009","article-title":"Resolvin E1 protects the rat heart against reperfusion injury","volume":"299","author":"Keyes","year":"2010","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.yjmcc.2015.04.003","article-title":"Resolvin D1 activates the inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function","volume":"84","author":"Kain","year":"2015","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"503128","DOI":"10.1155\/2012\/503128","article-title":"PGD Synthase and PGD2 in Immune Resposne","volume":"2012","author":"Joo","year":"2012","journal-title":"Mediat. Inflamm."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Li, K., Zhao, J., Wang, M., Niu, L., Wang, Y., Li, Y., and Zheng, Y. (2021). The Roles of Various Prostaglandins in Fibrosis: A Review. Biomolecules, 11.","DOI":"10.3390\/biom11060789"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2217\/clp.10.11","article-title":"Thromboxane and the thromboxane receptor in cardiovascular disease","volume":"5","author":"Smyth","year":"2010","journal-title":"Clin. Lipidol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1161\/CIRCRESAHA.115.305364","article-title":"The human microcirculation: Regulation of flow and beyond","volume":"118","author":"Gutterman","year":"2016","journal-title":"Circ. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00228-017-2242-2","article-title":"The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field","volume":"73","author":"Hoxha","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_65","first-page":"30","article-title":"The 5-lipoxygenase pathway in arterial wall biology and atherosclerosis","volume":"1736","author":"Lotzer","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"H495","DOI":"10.1152\/ajpheart.00349.2009","article-title":"Role of arachidonic acid lipoxygenase metabolites in the regulation of vascular tone","volume":"297","author":"Chawengsub","year":"2009","journal-title":"Am. J. Physiol. Heart Circ Physiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1194\/jlr.M061697","article-title":"Cytochrome P450-derived epoxyeicosatrienoic acids and coronary artery disease in humans: A targeted metabolomics study","volume":"57","author":"Edin","year":"2016","journal-title":"J. Lipid Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/1755-5922.12233","article-title":"Platelet activating factor: A potential biomarker in acute coronary syndrome?","volume":"35","author":"Ramakrishnan","year":"2017","journal-title":"Cardiovasc. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/09537109876672","article-title":"Association of platelet function in hypertensive patients with left ventricular hypertrophy, transient myocardial ischemia, and coronary artery disease","volume":"9","author":"Gabbasov","year":"1998","journal-title":"Platelets"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"684","DOI":"10.3109\/1354750X.2014.981293","article-title":"Correlation of platelet derived microparticles with thromboxane B2, platelet activating factor, endothelin 1 and neutrophil to lymphocyte ratio in patients with coronary intermediate lesion","volume":"8","author":"Chou","year":"2014","journal-title":"Biomarkers"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/00365510310003265","article-title":"Serum lysophosphatidic acid concentrations measured by dot immunogold filtration assay in patients with acute myocardial infarction","volume":"63","author":"Chen","year":"2003","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cca.2011.09.027","article-title":"Increased circulating plasma lysophosphatidic acid in patients with acute coronary syndrome","volume":"413","author":"Dohi","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1161\/01.CIR.0000083715.37658.C4","article-title":"Subtype-Selective Antagonists of Lysophosphatidic Acid Receptors Inhibit Platelet Activation Triggered by the Lipid Core of Atherosclerotic Plaques","volume":"108","author":"Rother","year":"2003","journal-title":"Circulation"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.2353\/ajpath.2010.091082","article-title":"Aspirin-Triggered Lipoxin and Resolvin E1 Modulate Vascular Smooth Muscle Phenotype and Correlate with Peripheral Atherosclerosis","volume":"177","author":"Ho","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.chembiol.2011.10.005","article-title":"Aspirin-Triggered Metabolites of EFAs","volume":"18","author":"Makriyannis","year":"2011","journal-title":"Chem. Biol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1172\/JCI97947","article-title":"Pro-resolving lipid mediators in vascular disease","volume":"128","author":"Conte","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"5249086","DOI":"10.1155\/2016\/5249086","article-title":"An Update of Microsomal Prostaglandin E Synthase-1 and PGE2Receptors in Cardiovascular Health and Diseases","volume":"2016","author":"Yang","year":"2016","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1476-5381.2011.01264.x","article-title":"Differential reactivity of human mammary artery and saphenous vein to prostaglandin E2: Implication for cardiovascular grafts","volume":"163","author":"Foudi","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1161\/ATVBAHA.112.254052","article-title":"Inactivation of the E-Prostanoid 3 Receptor Attenuates the Angiotensin II Pressor Response via Decreasing Arterial Contractility","volume":"32","author":"Chen","year":"2012","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1161\/HYPERTENSIONAHA.113.03051","article-title":"Prostaglandin I2 and Prostaglandin E2 Modulate Human Intrarenal Artery Contractility Through Prostaglandin E2-EP4, Prostacyclin-IP, and Thromboxane A2-TP Receptors","volume":"64","author":"Eskildsen","year":"2014","journal-title":"Hypertension"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1161\/CIRCULATIONAHA.107.749739","article-title":"Microsomal Prostaglandin E2 Synthase-1 Deletion Leads to Adverse Left Ventricular Remodeling After Myocardial Infarction","volume":"117","author":"Degousee","year":"2008","journal-title":"Circulation"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1124\/jpet.107.134221","article-title":"Cyclooxygenase-2-Linked Attenuation of Hypoxia-Induced Pulmonary Hypertension and Intravascular Thrombosis","volume":"326","author":"Cathcart","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"107624","DOI":"10.1016\/j.pharmthera.2020.107624","article-title":"Cyclooxygenases and the cardiovascular system","volume":"217","author":"Mitchell","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s10020-021-00358-4","article-title":"New horizons in the roles and associations of COX-2 and novel natural inhibitors in cardiovascular diseases","volume":"27","author":"Chen","year":"2021","journal-title":"Mol. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1365-2362.2010.02261.x","article-title":"Sulfido-peptide leukotrienes in coronary heart disease\u2014Relationship with disease instability and myocardial ischaemia","volume":"40","author":"Giannessi","year":"2010","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/ng1311","article-title":"The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke","volume":"36","author":"Helgadottir","year":"2004","journal-title":"Nat. Genet."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.plipres.2010.10.005","article-title":"Functional and pathological roles of the 12- and 15-lipoxygenases","volume":"50","author":"Dobrian","year":"2011","journal-title":"Prog. Lipid Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1084\/jem.20082596","article-title":"Cardiac 12\/15 lipoxygenase-induced inflammation is involved in heart failure","volume":"206","author":"Kayama","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_89","first-page":"H434","article-title":"Selective inhibition of angiotensin II-mediated vasoconstriction by lipoxygenase blockade","volume":"257","author":"Stern","year":"1989","journal-title":"Am. J. Physiol. Content"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.tox.2004.11.019","article-title":"Nitric oxide, peroxynitrite and lipoxygenase in atherogenesis: Mechanistic insights","volume":"208","author":"Rubbo","year":"2008","journal-title":"Toxicology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/j.1432-1033.1997.00608.x","article-title":"A kinetic model for the interaction of nitric oxide with a mammalian lipoxygenase","volume":"245","author":"Wiesner","year":"1997","journal-title":"Eur. J. Biochem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0163-7827(96)00008-2","article-title":"Biosynthesis, metabolization and biological importance of the primary 15-lipoxygenase metabolites 15-hydro(pero)xy-5Z,8Z,11Z,13E-eicosatetraenoic acid and 13-hydro(pero)xy-9Z,11E-octadecadienoic acid","volume":"35","year":"1996","journal-title":"Prog. Lipid Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.freeradbiomed.2014.08.007","article-title":"ROS-dependent Syk and Pyk2-mediated STAT1 activation is required for 15(S)-hydroxyeicosatetraenoic acid-induced CD36 expression and foam cell formation","volume":"76","author":"Kotla","year":"2014","journal-title":"Free Radic. Biol. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.atherosclerosis.2011.01.015","article-title":"12- and 15-lipoxygenases in human carotid atherosclerotic lesions: Associations with cerebrovascular symptoms","volume":"215","author":"Gertow","year":"2011","journal-title":"Atherosclerosis"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/humu.20273","article-title":"Functional polymorphism in ALOX15 results in increased allele-specific transcription in macrophages through binding of the transcription factor SPI1","volume":"27","author":"Wittwer","year":"2006","journal-title":"Hum. Mutat."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"642470","DOI":"10.3389\/fphys.2021.642470","article-title":"The Role of Epoxyeicosatrienoic Acids in Cardiac Remodeling","volume":"12","author":"Lai","year":"2021","journal-title":"Front. Physiol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00424-010-0804-6","article-title":"Epoxyeicosatrienoic acids and endothelium-dependent responses","volume":"459","author":"Campbell","year":"2010","journal-title":"Pflug. Arch."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000051053","article-title":"Epoxygenase Metabolites Contribute to Nitric Oxide-Independent Afferent Arteriolar Vasodilation in Response to Bradykinin","volume":"38","author":"Imig","year":"2001","journal-title":"J. Vasc. Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/sj.ki.5002394","article-title":"Roles of the cytochrome P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension","volume":"72","author":"Capdevila","year":"2007","journal-title":"Kidney Int."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1161\/hy0202.103788","article-title":"Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension","volume":"39","author":"Imig","year":"2002","journal-title":"Hypertension"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/STROKEAHA.109.567768","article-title":"Genetically Reduced Soluble Epoxide Hydrolase Activity and Risk of Stroke and Other Cardiovascular Disease","volume":"41","author":"Lee","year":"2010","journal-title":"Stroke"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1161\/ATVBAHA.109.186064","article-title":"Inhibition of Soluble Epoxide Hydrolase Attenuated Atherosclerosis, Abdominal Aortic Aneurysm Formation, and Dyslipidemia","volume":"29","author":"Zhang","year":"2009","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/FJC.0000000000000371","article-title":"CYP2J2 Overexpression Increases EETs and Protects Against HFD-Induced Atherosclerosis in ApoE\u2212\/\u2212 Mice","volume":"67","author":"Liu","year":"2016","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.yjmcc.2009.08.017","article-title":"Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches","volume":"47","author":"Li","year":"2009","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1755-5922.2010.00150.x","article-title":"Soluble Epoxide Hydrolase Inhibitors and Heart Failure","volume":"29","author":"Qiu","year":"2011","journal-title":"Cardiovasc. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.tips.2016.08.001","article-title":"Epoxyeicosatrienoic Acid as Therapy for Diabetic and Ischemic Cardiomyopathy","volume":"37","author":"Romashko","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"18733","DOI":"10.1073\/pnas.0609158103","article-title":"Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors","volume":"103","author":"Xu","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1124\/dmd.115.063776","article-title":"Early changes in cytochrome P450s and their associated arachidonic acid metabolites play a crucial role in the initiation of cardiac hypertrophy induced by isoproterenol","volume":"43","author":"Althurwi","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1111\/bph.12066","article-title":"Soluble epoxide hydrolase inhibitor, TUPS, protects against isoprenaline-induced cardiac hypertrophy","volume":"168","author":"Althurwi","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s12931-021-01891-w","article-title":"CYP2J2 and EETs protect against pulmonary arterial hypertension with lung ischemia\u2013reperfusion injury in vivo and in vitro","volume":"22","author":"Ding","year":"2021","journal-title":"Respir. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1084\/jem.192.8.1197","article-title":"Novel Functional Sets of Lipid-Derived Mediators with Antiinflammatory Actions Generated from Omega-3 Fatty Acids via Cyclooxygenase 2\u2013Nonsteroidal Antiinflammatory Drugs and Transcellular Processing","volume":"192","author":"Serhan","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"14609","DOI":"10.1021\/bi00044a041","article-title":"Design of Lipoxin A4 Stable Analogs That Block Transmigration and Adhesion of Human Neutrophils","volume":"34","author":"Serhan","year":"1995","journal-title":"Biochemistry"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"101068","DOI":"10.1016\/j.plipres.2020.101068","article-title":"Emerging roles of lysophospholipids in health and disease","volume":"80","author":"Tan","year":"2020","journal-title":"Prog. Lipid Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev.pharmtox.010909.105753","article-title":"LPA Receptors: Subtypes and Biological Actions","volume":"50","author":"Choi","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0090-6980(02)00058-8","article-title":"Platelet-activating factor receptor","volume":"68\u201369","author":"Ishii","year":"2002","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1124\/pr.107.07113","article-title":"\u201cInside-Out\u201d Signaling of Sphingosine-1-Phosphate: Therapeutic Targets","volume":"60","author":"Takabe","year":"2008","journal-title":"Pharmacol. Rev."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.1074\/jbc.M609641200","article-title":"A single enzyme catalyzes both platelet-activating factor production and membrane biogenesis of inflammatory cells: Cloning and characterization of acetyl-coa:lyso-paf acetyltransferase","volume":"282","author":"Shindou","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0090-6980(02)00023-0","article-title":"Platelet-activating factor acetylhydrolase","volume":"69","author":"Arai","year":"2002","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/oxfordjournals.jbchem.a003164","article-title":"Platelet-Activating Factor Receptor","volume":"131","author":"Honda","year":"2002","journal-title":"J. Biochem."},{"key":"ref_120","first-page":"479","article-title":"Platelet-activating factor receptor. Gene structure and tissue-specific regulation","volume":"416","author":"Shimizu","year":"1996","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1084\/jem.180.1.377","article-title":"Tumor necrosis factor alpha-induced angiogenesis depends on in situ platelet-activating factor biosynthesis","volume":"180","author":"Montrucchio","year":"1994","journal-title":"J. Exp. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.ajpath.2014.11.025","article-title":"The role of platelet activating factor in Mesangial Pathophysiology","volume":"185","author":"Reznichenko","year":"2015","journal-title":"Am. J. Pathol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000234755","article-title":"Role of cytokines and platelet activating factor in microvascular immune injury","volume":"88","author":"Braquet","year":"1989","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.neuron.2015.01.009","article-title":"Lysophosphatidic Acid Signaling in the Nervous System","volume":"85","author":"Yung","year":"2015","journal-title":"Neuron"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"851","DOI":"10.4049\/jimmunol.1302831","article-title":"The Autotaxin\u2013LPA Axis Emerges as a Novel Regulator of Lymphocyte Homing and Inflammation","volume":"192","author":"Knowlden","year":"2014","journal-title":"J. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1083\/jcb.200204026","article-title":"Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production","volume":"158","author":"Kishi","year":"2002","journal-title":"J. Cell Biol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"27855","DOI":"10.1074\/jbc.R111.254359","article-title":"Many Ceramides","volume":"286","author":"Hannun","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2174\/1874192401004010302","article-title":"The endothelium and its role in regulating vascular tone","volume":"4","author":"Sandoo","year":"2010","journal-title":"Open Cardiovasc. Med. J."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"McIntyre, T., Zimmerman, G.A., and Satoh, K. (1985). Cultured endothelial cells synthesize both PAF and prostacyclin in response to histamine, bradykinin and adenosine tri phosphate. J. Clin. Investig., 76271\u201376280.","DOI":"10.1172\/JCI111957"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"107404","DOI":"10.1016\/j.pharmthera.2019.107404","article-title":"Lysophosphatidic acid and its recep tors: Pharmacology and therapeutic potential in atherosclerosis and vascular disease","volume":"204","author":"Zhou","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.bbalip.2008.05.008","article-title":"Roles of lysophosphatidic acid in cardiovascular physiology and disease","volume":"1781","author":"Smyth","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_132","first-page":"96","article-title":"Vasopressor effect of lysophosphatidic acid on spontaneously hypertensive rats and Wistar Kyoto rats","volume":"90","author":"Tokumura","year":"1995","journal-title":"Res. Commun. Mol. Pathol. Pharmacol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1111\/bph.12678","article-title":"Lysophospholipid receptor nomenclature review: IUPHAR Review 8","volume":"171","author":"Kihara","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1084\/jem.20031619","article-title":"Lysophosphatidic Acid Induces Neointima Formation Through PPAR\u03b3 Activation","volume":"199","author":"Zhang","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bbrc.2008.04.145","article-title":"Identification of the orphan GPCR, P2Y10 receptor as the sphingosine-1-phosphate and lysophosphatidic acid receptor","volume":"371","author":"Murakami","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.omtm.2018.05.003","article-title":"Integrated Human Evaluation of the Lysophosphatidic Acid Pathway as a Novel Therapeutic Target in Atherosclerosis","volume":"10","author":"Aldi","year":"2018","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1042\/bj2910677","article-title":"The bioactive phospholipid lysophosphatidic acid is released from activated platelets","volume":"291","author":"Eichholtz","year":"1993","journal-title":"Biochem. J."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.bbalip.2008.06.005","article-title":"Two pathways for lysophosphatidic acid production","volume":"1781","author":"Aoki","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Yukiura, H., Kano, K., Kise, R., Inoue, A., and Aoki, J. (2015). Autotaxin Overexpression Causes Embryonic Lethality and Vascular Defects. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0126734"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1242\/jcs.172098","article-title":"LPP3 localizes LPA6 signalling to non-contact site in endothelial cells","volume":"128","author":"Yukiura","year":"2015","journal-title":"J. Cell Sci."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e10561","DOI":"10.7554\/eLife.10561","article-title":"Fibroblastic reticular cell-derived lysophosphatidic acid regulates confined intranodal T-cell motility","volume":"5","author":"Takeda","year":"2016","journal-title":"Elife"},{"key":"ref_142","first-page":"861","article-title":"Modulation of Hexadecyl-LPA-Mediated Activation of Mast Cells and Microglia by a Chemical Probe for LPA5","volume":"17","author":"Kozian","year":"2016","journal-title":"Chem. Biochem."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.bbrc.2017.07.159","article-title":"Lysophosphatidic acid directly induces macrophage-derived foam cell formation by blocking the expression of SRBI","volume":"491","author":"Chen","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3389\/fphys.2017.00266","article-title":"Lysophosphatidic Acid Is Associated with Atherosclerotic Plaque Instability by Regulating NF-\u03baB Dependent Matrix Metalloproteinase-9 Expression via LPA2 in Macrophages","volume":"8","author":"Gu","year":"2017","journal-title":"Front. Physiol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s11883-010-0159-7","article-title":"The Role of Matrix Metalloproteinases in Atherothrombosis","volume":"13","author":"Ketelhuth","year":"2011","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"eaar5551","DOI":"10.1126\/science.aar5551","article-title":"Sphingosine 1-phosphate: Lipid signaling in pathology and therapy","volume":"366","author":"Cartier","year":"2019","journal-title":"Science"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"26897","DOI":"10.1074\/jbc.M109.001677","article-title":"Ceramide 1-Phosphate Is Required for the Translocation of Group IVA Cytosolic Phospholipase A2 and Prostaglandin Synthesis","volume":"284","author":"Lamour","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_148","first-page":"351","article-title":"HDL quality or cholesterol cargo: What really matters\u2014Spotlight on sphingosine-1-phosphate-rich HDL","volume":"24","author":"Egom","year":"2013","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1007\/s00125-009-1482-9","article-title":"Link between plasma ceramides, inflammation and insulin resistance: Association with serum IL-6 concentration in patients with coronary heart disease","volume":"52","author":"Lankinen","year":"2009","journal-title":"Diabetologia"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nature13475","article-title":"Sphingolipid metabolites in inflammatory disease","volume":"510","author":"Maceyka","year":"2014","journal-title":"Nature"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/eurheartj\/ehx146","article-title":"Regulation of oxidized platelet lipidome: Implications for coronary artery disease","volume":"38","author":"Chatterjee","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.atherosclerosis.2015.10.022","article-title":"Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: Results of the ATHEROREMO-IVUS study","volume":"243","author":"Cheng","year":"2015","journal-title":"Atherosclerosis"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.it.2007.02.007","article-title":"Resolvins and protectins in the termination program of acute inflammation","volume":"28","author":"Ariel","year":"2007","journal-title":"Trends Immunol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.prostaglandins.2009.03.002","article-title":"Omega-3 PUFA derived anti-inflammatory lipid mediator resolvin E1","volume":"89","author":"Seki","year":"2009","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1039\/D0OB02218G","article-title":"Stereoselective syntheses and biological activities of E-series resolvins","volume":"19","author":"Vik","year":"2021","journal-title":"Org. Biomol. Chem."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/prd.12034","article-title":"Natural resolution of inflammation","volume":"63","author":"Freire","year":"2013","journal-title":"Periodontology 2000"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"10525","DOI":"10.1074\/jbc.M112.340612","article-title":"Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxyeicosapentaenoic acid","volume":"287","author":"Isobe","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"631319","DOI":"10.3389\/fimmu.2020.631319","article-title":"A New E-Series Resolvin: RvE4 Stereochemistry and Function in Efferocytosis of Inflammation-Resolution","volume":"11","author":"Libreros","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.mam.2017.03.005","article-title":"Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors","volume":"58","author":"Chiang","year":"2019","journal-title":"Mol. Asp. Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1084\/jem.20042031","article-title":"Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1","volume":"201","author":"Arita","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.4049\/jimmunol.178.6.3912","article-title":"Resolvin E1 Selectively Interacts with Leukotriene B4 Receptor BLT1 and ChemR23 to Regulate Inflammation","volume":"178","author":"Arita","year":"2007","journal-title":"J. Immunol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/nature05877","article-title":"Resolvin E1 and protectin D1 activate inflammation-resolution programmes","volume":"447","author":"Schwab","year":"2007","journal-title":"Nature"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.4049\/jimmunol.176.3.1848","article-title":"Anti-Inflammatory Actions of Neuroprotectin D1\/Protectin D1 and Its Natural Stereoisomers: Assignments of Dihydroxy-Containing Docosatrienes","volume":"176","author":"Serhan","year":"2006","journal-title":"J. Immunol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.4049\/jimmunol.1101305","article-title":"Omega-3 Fatty Acid-Derived Mediators 17(R)-Hydroxy Docosahexaenoic Acid, Aspirin-Triggered Resolvin D1 and Resolvin D2 Prevent Experimental Colitis in Mice","volume":"187","author":"Bento","year":"2011","journal-title":"J. Immunol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1172\/JCI25420","article-title":"A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease","volume":"115","author":"Lukiw","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"8491","DOI":"10.1073\/pnas.0402531101","article-title":"Neuroprotectin D1: A docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress","volume":"101","author":"Mukherjee","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/j.1582-4934.2008.00387.x","article-title":"Endogenous anti-inflammatory neuropeptides and pro-resolving lipid mediators: A new therapeutic approach for immune disorders","volume":"12","author":"Anderson","year":"2008","journal-title":"J. Cell. Mol. Med."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1038\/sj.bjp.0707489","article-title":"Endogenous pro-resolving and anti-inflammatory lipid mediators: A new pharmacologic genus","volume":"153","author":"Serhan","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.bbalip.2014.08.006","article-title":"Protectins and maresins: New pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome","volume":"1851","author":"Serhan","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3389\/fimmu.2012.00081","article-title":"Functional Metabolomics Reveals Novel Active Products in the DHA Metabolome","volume":"3","author":"Shinohara","year":"2012","journal-title":"Front. Immunol."},{"key":"ref_171","first-page":"7442","article-title":"Maresins: Anti-inflammatory pro-resolving mediators with therapeutic potential","volume":"24","author":"Li","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.4049\/jimmunol.179.10.7021","article-title":"Resolvin E1 Regulates Inflammation at the Cellular and Tissue Level and Restores Tissue Homeostasis In Vivo","volume":"179","author":"Hasturk","year":"2007","journal-title":"J. Immunol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"0094","DOI":"10.1038\/s41551-017-0094","article-title":"Microscale arrays for the profiling of start and stop signals coordinating human-neutrophil swarming","volume":"1","author":"Jalali","year":"2017","journal-title":"Nat. Biomed. Eng."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1172\/JCI42545","article-title":"Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation","volume":"121","author":"Oh","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2796.2010.02235.x","article-title":"Profiling in resolving inflammatory exudates identifies novel anti-inflammatory and pro-resolving mediators and signals for termination","volume":"268","author":"Norling","year":"2010","journal-title":"J. Intern. Med."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1084\/jem.20081880","article-title":"Maresins: Novel macrophage mediators with potent antiinflammatory and proresolving actions","volume":"206","author":"Serhan","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41467-017-02538-5","article-title":"Human macrophages differentially produce specific resolvin or leukotriene signals that depend on bacterial pathogenicity","volume":"9","author":"Werz","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_178","first-page":"e94463","article-title":"Pro-resolving mediators promote resolution in a human skin model of UV-killed Escherichia coli\u2013driven acute inflammation","volume":"3","author":"Motwani","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.3389\/fimmu.2017.01400","article-title":"Pro-Resolving Mediators in Regulating and Conferring Macrophage Function","volume":"8","author":"Dalli","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1161\/ATVBAHA.110.209908","article-title":"Resolvin E1 Regulates Adenosine Diphosphate Activation of Human Platelets","volume":"30","author":"Fredman","year":"2010","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1111\/bph.13707","article-title":"Aspirin-triggered lipoxin A4 inhibits atherosclerosis progression in apolipoprotein E\u2212\/\u2212mice","volume":"174","author":"Petri","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mam.2017.08.002","article-title":"New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration","volume":"64","author":"Serhan","year":"2018","journal-title":"Mol. Asp. Med."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/S1734-1140(12)70950-7","article-title":"EP3 receptor-mediated contraction of human pulmonary arteries and inhibition of neurogenic tachycardia in pithed rats","volume":"64","author":"Schlicker","year":"2012","journal-title":"Pharmacol. Rep."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/jth.13620","article-title":"Maresin 1 induces a novel pro-resolving phenotype in human platelets","volume":"15","author":"Lannan","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"16526","DOI":"10.1073\/pnas.1407123111","article-title":"Maresin 1 biosynthesis during platelet\u2013neutrophil interactions is organ-protective","volume":"111","author":"Abdulnour","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/blood-2007-11-122598","article-title":"Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets","volume":"112","author":"Dona","year":"2008","journal-title":"Blood"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1096\/fj.201500155R","article-title":"Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling","volume":"30","author":"Elajami","year":"2016","journal-title":"FASEB J."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/CIRCRESAHA.116.307308","article-title":"Resolution of Acute Inflammation and the Role of Resolvins in Immunity, Thrombosis, and Vascular Biology","volume":"119","author":"Sansbury","year":"2016","journal-title":"Circ. Res."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1182\/blood.V94.12.4132","article-title":"Anti-inflammatory actions of lipoxin A(4) stable analogs are demonstrable in human whole blood: Modulation of leukocyte adhesion molecules and inhibition of neutrophil-endothelial interactions","volume":"94","author":"Filep","year":"1999","journal-title":"Blood"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.freeradbiomed.2018.01.034","article-title":"Resolvin D1 blocks H2O2-mediated inhibitory crosstalk between SHP2 and PP2A and suppresses endothelial-monocyte interactions","volume":"117","author":"Chattopadhyay","year":"2018","journal-title":"Free Radic. Biol. Med."},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Chatterjee, A., Sharma, A., Chen, M., Toy, R., Mottola, G., and Conte, M.S. (2014). The Pro-Resolving Lipid Mediator Maresin 1 (MaR1) Attenuates Inflammatory Signaling Pathways in Vascular Smooth Muscle and Endothelial Cells. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0113480"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.redox.2017.02.023","article-title":"Resolvin D1 via prevention of ROS-mediated SHP2 inactivation protects endothelial adherens junction integrity and barrier function","volume":"12","author":"Chattopadhyay","year":"2017","journal-title":"Redox Biol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1096\/fj.12-225615","article-title":"D-series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury","volume":"27","author":"Miyahara","year":"2013","journal-title":"FASEB J."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jvs.2016.01.030","article-title":"Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rat model of arterial injury","volume":"65","author":"Wu","year":"2017","journal-title":"J. Vasc. Surg."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/sj.ejcn.1602523","article-title":"Influence of three rapeseed oil-rich diets, fortified with \u03b1-linolenic acid, eicosapentaenoic acid or docosahexaenoic acid on the composition and oxidizability of low-density lipoproteins: Results of a controlled study in healthy volunteers","volume":"61","author":"Egert","year":"2007","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s11745-001-0812-7","article-title":"Polyunsaturated fatty acids, inflammation, and immunity","volume":"36","author":"Calder","year":"2000","journal-title":"Lipids"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40169-017-0153-6","article-title":"Significance of long chain polyunsaturated fatty acids in human health","volume":"6","author":"Tejera","year":"2017","journal-title":"Clin. Transl. Med."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.plefa.2009.01.004","article-title":"International Society for the Study of Fatty Acids and Lipids, ISSFAL. \u03b1-Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans","volume":"80","author":"Brenna","year":"2009","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.plefa.2017.08.007","article-title":"Circulating inflammation-resolving lipid mediators RvD1 and DHA are decreased in patients with acutely symptomatic carotid disease","volume":"125","author":"Bazan","year":"2017","journal-title":"Prostaglandins, Leukot. Essent. Fat. Acids"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.plefa.2018.03.010","article-title":"Supplementation with eicosapentaenoic acid and docosahexaenoic acid reduces high levels of circulating proinflammatory cytokines in aging adults: A randomized, controlled study","volume":"132","author":"Tan","year":"2018","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1016\/S0140-6736(99)90191-5","article-title":"GISSI-Prevenzione trial. GISSI-Prevenzione trial","volume":"354","author":"Jialal","year":"1999","journal-title":"Lancet"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"809311","DOI":"10.3389\/fnut.2022.809311","article-title":"Omega-3 Fatty Acid Supplementation and Coronary Heart Disease Risks: A Meta-Analysis of Randomized Controlled Clinical Trials","volume":"9","author":"Shen","year":"2022","journal-title":"Front. Nutr."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.jacc.2019.02.032","article-title":"REDUCE-IT Investigators. Effects of icosapent ethyl on total ischemic events: From REDUCE-IT","volume":"73","author":"Bhatt","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.121.055654","article-title":"Effect of Long-Term Marine \u0277-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis","volume":"144","author":"Gencer","year":"2021","journal-title":"Circulation"},{"key":"ref_206","first-page":"8526","article-title":"Effects of omega-3 polyunsaturated fatty acids supplementation for patients with cardiovascular disease risks: A dose-response meta-analysis","volume":"13","author":"Xie","year":"2021","journal-title":"Am. J. Transl. Res."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jand.2018.02.004","article-title":"Inuit Country Food Diet Pattern Is Associated with Lower Risk of Coronary Heart Disease","volume":"118","author":"Hu","year":"2018","journal-title":"J. Acad. Nutr. Diet."},{"key":"ref_208","first-page":"201","article-title":"An overview of the modulatory effects of oleic acid in health and disease","volume":"13","author":"Souza","year":"2013","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.amjmed.2014.10.014","article-title":"The Mediterranean Diet, its Components, and Cardiovascular Disease","volume":"128","author":"Widmer","year":"2015","journal-title":"Am. J. Med."},{"key":"ref_210","doi-asserted-by":"crossref","unstructured":"Liyanage, T., Ninomiya, T., Wang, A., Neal, B., Jun, M., Wong, M.G., Jardine, M., Hillis, G.S., and Perkovic, V. (2016). Effects of the Mediterranean Diet on Cardiovascular Outcomes\u2014A Systematic Review and Meta-Analysis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0159252"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.neurol.2019.08.005","article-title":"Mediterranean diet: The role of long-chain \u03c9-3 fatty acids in fish; polyphenols in fruits, vegetables, cereals, coffee, tea, cacao and wine; probiotics and vitamins in prevention of stroke, age-related cognitive decline, and Alzheimer disease","volume":"175","author":"Jackson","year":"2019","journal-title":"Rev. Neurol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jacc.2009.02.084","article-title":"Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Diseases","volume":"54","author":"Lavie","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1991S","DOI":"10.1093\/ajcn\/87.6.1991S","article-title":"Fish and n\u22123 fatty acids for the prevention of fatal coronary heart disease and sudden cardiac death","volume":"87","author":"Mozaffarian","year":"2008","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1161\/CIRCULATIONAHA.110.948562","article-title":"OMEGA Study Group. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction","volume":"122","author":"Rauch","year":"2010","journal-title":"Circulation"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4330\/wjc.v8.i2.114","article-title":"Omega 3 and atrial fibrillation: Where are we?","volume":"8","author":"Martino","year":"2016","journal-title":"World J. Cardiol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/2012.jama.11374","article-title":"Association Between Omega-3 Fatty Acid Supplementation and Risk of Major Cardiovascular Disease Events: A systematic review and meta-analysis","volume":"308","author":"Rizos","year":"2012","journal-title":"JAMA"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1161\/01.CIR.0000132503.19410.6B","article-title":"Accumulated Evidence on Fish Consumption and Coronary Heart Disease Mortality","volume":"109","author":"He","year":"2004","journal-title":"Circulation"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1203859","article-title":"n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia","volume":"367","author":"Bosch","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mayocp.2016.10.018","article-title":"A meta-analysis of randomized controlled trials and prospective cohort studies of eicosapentaenoic and docosahexaenoic long-chain omega-3 fatty acids and coronary heart disease risk","volume":"Volume 92","author":"Alexander","year":"2017","journal-title":"Mayo Clinic Proceedings"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamacardio.2017.5205","article-title":"Omega-3 Treatment Trialists\u2019 Collaboration. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: Meta-analysis of 10 trials involving 77917 individuals","volume":"3","author":"Aung","year":"2018","journal-title":"JAMA Cardiol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejphar.2015.08.049","article-title":"COX-2, aspirin and metabolism of arachidonic, eicosapentaenoic and docosahexaenoic acids and their physiological and clinical significance","volume":"785","author":"Poorani","year":"2016","journal-title":"Eur. J. Pharmacol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/2\/1637\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:05:42Z","timestamp":1760119542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/2\/1637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":221,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["ijms24021637"],"URL":"https:\/\/doi.org\/10.3390\/ijms24021637","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]}}}